• Most Popular
  • Most Shared

Glaxo says cervical cancer vaccine works for longer

LONDON
Wed May 14, 2008 4:19am EDT

LONDON (Reuters) - GlaxoSmithKline said on Wednesday new data showed its Cervarix vaccine generated sustained, high levels of neutralizing antibodies against the two most common cervical cancer-causing virus types for 6.4 years.

Health  |  Stocks  |  Global Markets

Glaxo said on Wednesday the data, from an extended follow-up study, showed the longest duration of sustained neutralizing antibody levels reported against both virus types HPV 16 and 18 with a cervical cancer vaccine to date.

Experts believe that neutralizing antibodies -- so-called because they have the ability to neutralize cancer-causing virus types and prevent them from infecting cells in the cervix -- are essential for cervical cancer protection.

(Reporting by Mark Potter, Editing by Dan Lalor)
Health
Stocks
Global Markets


More from Reuters

Photo

Fox, Time Warner Cable ink deal to avoid blackout

NEW YORK (Reuters) - Time Warner Cable and News Corp's Fox Networks Group agreed to a brief extension of their current carriage contract late on Thursday to avoid a blackout that would have prevented 13 million U.S. homes from seeing TV shows like "The Simpsons" and "House" as well as college and NFL football games.

» More Top News
A customer is served at a counter inside a foreign exchange store displaying a poster of various banknotes including the Chinese yuan or renminbi (RMB) in Hong Kong November 20, 2009. REUTERS/Bobby Yip
OUTLOOK 2010:

Be careful what you wish for

Pressure on China to loosen its grip on the yuan will continue but the U.S. should tread carefully. Here are five world market issues to watch.  Full Article 

Global Markets
Clients work out on machines at the Bally Total Fitness facility in Arvada, Colorado June 15, 2009. REUTERS/Rick Wilking

Get real with resolutions

We make them and we break them: The secret to keeping them is to avoid the impossible dream.  Full Article 

Lifestyle